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Abstract
Summary We aimed to understand how patients 50 years and
older decided to persist with or stop osteoporosis (OP) treat-
ment. Processes related to persisting with or stopping OP
treatments are complex and dynamic. The severity and risks
and harms related to untreated clinical OP and the favorable
benefit-to-risk profile for OP treatments should be reinforced.
Introduction Older adults with fragility fracture and clinical
OP are at high risk of recurrent fracture, and treatment reduces
this risk by 50 %. However, only 20 % of fracture patients are
treated for OP and half stop treatment within 1 year. We aimed
to understand how older patients with new fractures decided to
persist with or stop OP treatment over 1 year.
Methods We conducted a grounded theory study of patients
50 years and older with upper extremity fracture who started
bisphosphonates and then reported persisting with or stopping
treatment at 1 year. We used theoretical sampling to identify
patients who could inform emerging concepts until data
saturation was achieved and analyzed these data using con-
stant comparison.
Results We conducted 21 interviews with 12 patients.
Three major themes emerged. First, patients perceived
OP was not a serious health condition and considered
its impact negligible. Second, persisters and stoppers
differed in weighting the risks vs benefits of treatments,
where persisters perceived less risk and more benefit.
Persisters considered treatment Brequired^ while stop-
pers often deemed treatment Boptional.^ Third, patients
could change treatment status even 1-year post-fracture
because they re-evaluated severity and impact of OP vs
risks and benefits of treatments over time.
Conclusions The processes and reasoning related to
persisting with or stopping OP treatments post-fracture
are complex and dynamic. Our findings suggest two
areas of leverage for healthcare providers to reinforce
to improve persistence: (1) the severity and risks and
harms related to untreated clinical OP and (2) the favor-
able benefit-to-risk profile for OP treatments.
Keywords Adherence . Fragility fractures . Grounded
theory . Osteoporosis . Persistence . Treatment
Introduction
Osteoporosis (OP) is a chronic condition associated with
increased morbidity and mortality and decreased quality
of life [1, 2]. Older adults who fracture have a 20 %
risk of another fracture within 1 year [1–3] and treat-
ment with a bisphosphonate reduces this risk by 50 %
[4–6]. As such, the focus of the 2010 Osteoporosis
Canada Guidelines (as well as guidelines endorsed by
the National Osteoporosis Foundat ion and the
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International Osteoporosis Foundation) is secondary pre-
vention. This entails identifying patients with fragility
fractures of the upper extremity, spine, or hip, ordering
bone mass density (BMD) tests and offering treatment
to those at the highest risk of another fracture [7–9].
Regardless of this guidance, less than 20 % of people
are treated for OP in the year post-fracture [1, 2, 6, 9].
Equally worrisome, of those written a prescription for
OP treatment, 30 % will not fill their prescription
(primary non-adherence) [10] and of those who do fill
their first prescription, at least half will stop treatment
within 1 year [11, 12]. Indeed, even in the setting of a
randomized trial to improve testing and treatment of OP
after a fragility fracture, 18 % of those who started
treatment in the intervention arm had stopped treatment
within 1 year [13]. Several models address how individ-
ual factors, such as knowledge and attitudes, and social
processes, including identity and support, influence be-
haviors [14]. However, the patient-level factors related
to starting and stopping OP treatments remain relatively
under studied and yet critically important to understand
[15–17].
To better understand long-term persistence (and non-
persistence) with OP treatments, we capitalized on partici-
pants in the Comparing Strategies Targeting Osteoporosis to
Prevent Recurrent Fractures (C-STOP) trial. This trial, based
on a positive pilot study [18], is currently enrolling patients
with upper extremity fragility fractures in an active-
comparator randomized controlled trial of nurse case manage-
ment vs a multifaceted intervention directed at patients (i.e.,
printed materials, education, telephonic counseling) and their
physicians (i.e., reminders, opinion leader endorsed guide-
lines). The nurse case-manager identifies and interviews pa-
tients from clinic settings (Emergency Departments and
Fracture Clinics), arranges BMD tests, and offers in-person
education, counseling, and guideline-based prescription treat-
ments as needed, and then follows patients up for 1 year.
Patients in the case-manager arm of this study represented
the Bbest-case scenario.^ For example, they are relatively
healthy although they have all recently suffered a fragility
fracture and are all at similar risk of re-fracture based on the
most recent major osteoporotic fracture and calculated FRAX
with BMD scores of moderate to high risk. In addition, they
all received standardized print materials with in-person
counseling and were all offered treatment based upon stan-
dardized treatment algorithms [18]. In this setting of uniform
care, we hypothesized we might be able to gain important and
nuanced insights into patient-specific reasons for continuing
or quitting OPmedications. Therefore, rather than use surveys
or secondary analyses of various databases as has been done
previously [3, 15, 16, 19–21], we undertook a qualitative
grounded theory study to understand the processes and rea-
soning that adults 50 years and older with recent fragility
fractures go through when deciding to persist with or stop
bisphosphonates in the 1-year post-fracture.
Methods
We used a grounded theory approach as outlined by Corbin
and Strauss [22] to understand the processes and reasoning
people engage in when deciding to persist with or stop OP
medications in general, and more specifically, bisphosphonate
treatment after suffering a fragility fracture of the upper ex-
tremity. Grounded theory is an inductive approach where
models or concepts are Bgrounded^ in the data collected with-
out an a priori hypothesis. We chose to use a grounded theory
approach to understand how patients approach a diagnosis of
OP and how they negotiate persisting with or stopping treat-
ment. We considered all of these patients (50 years and older
with fragility fracture of the distal radius or proximal humerus
and low bone mass at one or more skeletal sites) to have a
clinical diagnosis of OP [23] and refer to this as OP through-
out. When referring to BMD test results alone, we refer to
osteopenia (T-score ≤1.0 to −2.5) or OP (T-score ≤2.5) [18,
23] and always make this distinction explicit.
Data collection and measurements
The primary study outcomes of the larger C-STOP trial were
ascertained at 6 months, and the research team remained
blinded to these data. That said, during 1-year follow-up of
this population, we identified nurse case-management patients
who had started bisphosphonate treatment at any time up to
their 1-year data collection. We enrolled 150 patients in the
nurse case-management arm of the larger study. Thus, all pa-
tients seen in the clinic were potentially eligible, and the only
patients seen in the clinic were trial patients. We did not sam-
ple patients Brandomly^ for the purposes of generalizability of
the results as conceptualized in quantitative research. Instead,
we sampled patients based on their ability to act as key infor-
mants (i.e., someone with direct experience with the phenom-
enon who is able to reflect on and articulate their experience)
for the purposes of transferability of the results to similar
populations and contexts. At this time, we purposefully sam-
pled patients who had started bisphosphonate treatment (by
study treatment algorithm, either generic alendronate or
risedronate prescribed weekly [18]) and reported whether they
were still persistent with treatment at 1 year (Bpersisters^) or
they had stopped treatment (Bstoppers^). We verified all self-
reported treatment data independently by using local pharma-
cy dispensing records.
As the study progressed, we used theoretical sampling, one
of the core strategies of grounded theory [22, 24]. Theoretical
sampling is responsive to the data in that the researchers sam-
ple concepts and not persons [22]. Since the nurse case-
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manager had met and remained in contact with all trial pa-
tients, she helped identify potential patients who could talk
directly to our various emerging concepts. For example, we
recruited patients diagnosed with either osteopenia or OP as
defined strictly by BMD test results to elicit a deeper under-
standing of perceived severity, when this specific concept
emerged from analysis. As well, we re-interviewed several
patients as themes and concepts emerged.
A trained researcher conducted qualitative in-person inter-
views using a semi-structured interview guide (Appendix),
which was refined as data analysis progressed. Interviews
were conducted in the same location as case-management ap-
pointments at a single center and lasted up to 45 min.
Interviews were digitally recorded for subsequent analysis
and verified for accuracy. The University of Alberta Health
Ethics Research Board approved the parent trial and this qual-
itative sub-study, and all subjects provided written informed
consent.
Analysis
We used constant comparison to analyze the data, using open
coding and memos [22, 25, 26]. One analyst (LW) identified
emerging codes and concepts. The research team held regular
meetings to review code definitions, emerging concepts, and
memos and to refine the interview guide. We conducted data
collection and analysis concurrently until theoretical data sat-
uration [27, 28] was achieved, that is, the major concepts were
well defined and explained and no new concepts or themes
emerged [22]. We implemented several strategies throughout
the research process to ensure rigor including methodological
coherence [29], peer debriefing [24], reflective writing [22],
and maintaining an audit trail [24]. Data were managed and
analyzed using Atlas.ti version 7 (Berlin, Germany, Scientific
Software Development GmbH) [30].
Results
From April 2014 through March 2015, we conducted 21 in-
terviews with 12 different patients, including a second follow-
up interview with the initial 9 patients to address questions
that emerged through concurrent data collection and analysis.
Of the 12 patients recruited, 7 persisted with bisphosphonates
and 5 stopped. Treatment status was determined at the last
point of contact (e.g., a patient who was a persister at her first
interview but a stopper at her second interview was classified
as a stopper). Of note, three patients changed their treatment
status during the study. Two thirds of patients were 60 years or
older, 75 % were women, 67 % had osteopenia (T-score ≤1.0)
at one or more skeletal sites according to BMD testing, and
92 % had better-than-average OP-related knowledge com-
pared with the average score (57 %) reported previously in a
similar trial population [31] (Table 1). By trial design, no
patient had been taking OPmedications at the time of fracture.
Three major themes emerged. We provide a list of codes,
sub-codes, and supplemental illustrative quotes that comprise
each theme in Table 2, and we detail each theme below.
Theme 1: negligible appreciation of risk
regarding severity and impact of OP
Regardless of treatment status, patients identified similar rea-
sons for deciding to start bisphosphonates. These reasons in-
cluded: (1) being advised to do so by a healthcare professional,
(2) to prevent the progression of their condition or to maintain
current bone health, or (3) to stay healthy.
Nonetheless, and despite the fact that all but one of these
patients had better-than-average OP-related knowledge, they
did not consider OP to be a serious health condition, particu-
larly compared with other diseases like cancer. Furthermore,
based on their understanding of their own BMD test results,
patients (all of whom had a fragility fracture) perceived a test
result of osteopenia as less serious than OP and defined it as
pre- or borderline-OP, at the beginning stages of OP, or within
acceptable range. In addition, patients were not concerned
about their bone health or OP prior to their fracture. Many
patients believed OP was a natural part of aging, especially
for women, and some commented that they did not experience
symptoms or feel differently because they now had an OP
diagnosis.
Of particular note, patients generally perceived minimal
susceptibility to the potential negative consequences of OP
in the future. They believed that it was in their control to
prevent future fractures by being more careful or avoiding
falls. From their perspective, the fracture was their fault.
However, some patients said the fracture was unavoidable or
would have happened to anyone, indicating that it was not a
result of compromised bone health. Generally, patients ex-
plained that an upper extremity fracture did not affect their
lives substantially in the way that a hip fracture would.
Theme 2: ongoing evaluation of risks vs benefits
of treatments
The main difference between patients who persisted with or
stopped taking bisphosphonates was in their evaluation of its
risks and benefits. Patients who persisted perceived greater
benefit than risk from taking OP medications. They believed
that medication was required or the best option to treat their
condition. In addition, they perceived their risk of future
fracture without OP treatment as high and said they
would continue taking prescription treatment even if
they had another fracture. Lastly, they did not report
experiencing any side effects.
Osteoporos Int (2017) 28:219–229 221
In contrast, patients who stopped treatment within 1 year
believed that bisphosphonate treatment was optional and no
more beneficial than exercising and taking vitamin D and
calcium. They perceived their risk of future fracture without
treatment as low. In addition, they reported concerns about
side effects and this was enough to tip the balance towards
non-persistence.
Theme 3: re-evaluation of severity and impact of OP vs
risks and benefits of treatment over time
Patients reported changing (or having the potential to change)
treatment status even 1-year post-fracture because they
reassessed the severity and impact of OP as well as the risks
and benefits of bisphosphonate treatment over time. Two pa-
tients who restarted OP medications after initially quitting
explained that they have OP (rather than just osteopenia ac-
cording to a BMD test) and that prescription treatment was
now required rather than optional. Conversely, the patient
who persisted with bisphosphonates but then stopped 1-year
post-fracture explained that she had osteopenia, and not OP,
according to her BMD tests and that there had been no further
decline in her bone health as far as she could tell. In addition,
she explained prescription treatment was but one option and
not necessary to treat OP. Lastly, she reported experiencing
what she perceived as side effects of bisphosphonates, includ-
ing pain in her hip when laying down.
Even patients who did not change treatment status reported
the potential to change status at almost any time post-fracture.
For example, patients who persisted with treatment described
Blapses^ in adherence, primarily when traveling. One patient
commented that she forgot to take her medication while trav-
eling because OP is not life threatening. In addition, patients
who persisted reported the potential to stop taking OP medi-
cations in the future if, for example, they started experiencing
side effects or saw no improvement in their BMD test results.
On the other hand, several patients who stopped explained that
they would consider re-starting treatment in the future if, for
example, they were diagnosed with OP (rather than
osteopenia) based on their BMD results, believed that OP
could affect their life negatively, or were informed that
bisphosphonates were their best treatment option. For exam-
ple, the patient who stopped prescription treatment 1-year
post-fragility fracture said that she would re-start if her family
physician diagnosed her with OP and told her that OP medi-
cations were required to treat it.
Discussion
In this grounded theory study examining how patients’ under-
stand the clinical problem of OP and how they decided to
persist with or stop treatment 1-year post-fracture, three broad
themes emerged. First, patients perceived that OP was not a
serious health condition and that its impact was negligible
regardless of their decision to start treatment. Second, the
main difference between persisters and stoppers was in their
ongoing evaluation of the risks vs benefits of bisphosphonate
treatment, where patients who persisted perceived more ben-
efit and less risk than patients who stopped. Third, we found
that patients had the potential to change treatment status even
1-year post-fracture because they re-evaluated the severity and
impact of OP vs the risks and benefits of treatments over time.
We have attempted to represent and conceptualize this
decision-making process in Fig. 1.
Table 1 Patient characteristics
according to treatment status Treatment status
a Total (n = 12) Persisted (n = 7) Stopped (n = 5)
# (%) # (%) # (%)
Age >60 years 8 (67) 5 (71) 3 (60)
Female 9 (75) 5 (71) 4 (80)
White 12 (100) 7 (100) 5 (100)
BMD test results
Osteoporosis (T-score less than −2.5) 4 (33) 2 (29) 2 (40)
Osteopenia (T-score −1.0 to −2.4) 8 (67) 5 (71) 3 (60)
FRAX score
High 10-year risk 2 (17) 1 (14) 1 (20)
Moderate 10-year risk 10 (83) 6 (86) 4 (80)
Above average OP-related knowledgeb 11 (92) 6 (86) 5 (100)
a Treatment status was determined based on status at the last point of contact (e.g., a patient who was a persister at
her first interview but a stopper at her second interview was classified as a stopper)
b The average score (a percentage of correct answers with a higher percentage representing more knowledge) of
OP-related knowledge as measured by the 25-item facts on osteoporosis quiz [52] was previously determined in
this patient population to be 57 % [31]
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Table 2 Codes, sub-codes, and selected supporting quotes by three main themes
Codes and sub-codes Selected supporting quotes
Theme 1: negligible appreciation of risk regarding severity and impact of OP
Reason for deciding to start prescription treatment
Advised by healthcare professional I think it’s to do with the way I was brought up, to do what the doctor tells me
(laughing) (female, age 67, persister).
[I decided to start prescription treatment] just because [the case-management RN]
recommended it or said that it would might be helpful to strengthen the bones
(male, age 67, stopper).
Prevent progression or maintain bone health Just the whole idea that I want to prolong the osteopenia and not actually be
classified as osteoporotic. So I guess that’s your Bcarrot dangled in front of you^,
because you don’t want it to get any worse. (female, age 55, changed to stopper).
To stay healthy I think you know when you get to my age, you’ve got enough to worry about.
Like with health issues you know. There’s breast cancer and there’s heart
problems. So I mean I think if we can try to keep ourselves healthy, I think
that’s a really good thing (female, age 67, persister).
Clinical OP is not serious
Compared with other life-threatening diseases Cancer to me is kind of a death sentence. It doesn’t have to be, but it’s more like
that whereas I think high blood pressure and OP are more the quality of life kind
of a thing (male, age 60, persister).
It could be cancer for heaven’s sake. So this is way better (female, age 55, changed
to stopper).
Cancer seems to be more life threatening than OP (male, age 67, stopper).
Osteopenia is pre- or borderline-OP, at the beginning
stages, or within an acceptable range
I don’t think it’s pronounced—I mean, I’m just in the beginning stages… So it’s not
an advanced case (female, age 68, persister).
I guess to me the easiest way of saying it was when my husband’s doctor said, you
don’t have diabetes yet, you have pre-diabetes. So it is that we have a problem
that we are seeing coming, it’s not really there yet, but it’s heading in that
direction so… Flag there is a problem, but it isn’t as bad as OP (female, age
68, changed to persister).
I don’t believe I have OP. I might have had some bone loss with the bone
density, but it’s still within an acceptable range (female, age 70, stopper).
Not concerned about bone health or clinical OP
before fracture
I had broken this bone about seven or eight years before and they said that there
was a weakness of bone but over that time it didn’t bother me. I wasn’t
concerned about it (male, age 67, stopper).
I mean I’ve always been active, I do a lot of walking, I do a lot of exercise. I keep
active. I have a pretty good diet. So it was not anything I thought I needed to
think about (female, age 68, changed to persister).
Clinical OP is a natural part of aging for women I guess all women’s bones must deteriorate. I mean I’m sure they do after a
certain age and maybe a surprisingly young age (female, age 67, persister).
I know that it happens as you get older (female, age 70, stopper).
No symptoms or I don’t feel different To be honest I was very surprised when they tested me and I was low on calcium
and vitamin D and the bone density was down, borderline-OP. It was just a big
surprise. I didn’t have any symptoms (male, age 60, persister).
Arthritis takes away your independence too, and it takes away your comfort…
[With OP,] you don’t even know it’s there (female, age 70, stopper).
Minimum perceived susceptibility
Future fractures are preventable I was just walking in the neighborhood and it was literally ice that was covered with
snow. But it was largely my own fault. I just wasn’t being as cautious as I should
have been. You know (laughing), that’s always easy to see the mistake after
(female, age 67, persister).
But with broken bones, I just write it off to my clumsiness (laughing)… You still
have to be careful and sometimes I’m not. Nod off sometimes when I should be
paying attention (male, age 67, stopper).
Unavoidable fracture They said it was an unusual [fracture] because I was just falling from standing, but
I was also carrying some heavy stuff and it all came down mostly on the one
arm. And it was right on concrete so it was hard and it was slippery so it was
harder, so everything (male, age 60, persister).
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Table 2 (continued)
Codes and sub-codes Selected supporting quotes
I think that the stupid way I fell - I don’t know if it would have been any different
if I had been 20 or 18 or 12. It might have just been the way I fell versus a concern
about osteo’ (female, age 68, changed to persister).
Upper extremity fracture had a minimal impact; hip
fracture could be worse
I mean the wrist was a wrist. If it had been a hip it’s going to have a more an impact.
If it’s an ankle a bit more of an impact too. It didn’t prevent me from doing what I
wanted to do (female, age 68, changed to persister).
My adopted mom, she was watering her flowers and all of a sudden, her hip gave
way. Well, that’s a red flag (female, age 70, stopper).
Theme 2: ongoing evaluation of risks vs benefits of
treatments
Benefits outweighed risks for patient who persisted
Prescription treatment is required to treat clinical OP Well I don’t know that there’s a lot else you can do for OP other than exercise and
taking the Alendronate (female, age 67, persister).
I didn’t have an option [to take prescription treatment], that’s the way it occurred, I
didn’t have an option. I’m not going to any health food medicine or this or that. No
way. Oh maybe some of them are very good, but no, I’m not going to do that.
I’m going to do what conventional medicine said I should do (male, age 76,
persister).
Perceived high to medium risk of future fracture
without prescription treatment
Just from what they’ve told me and cause I’m active in doing things and with
loss of 20 % of your bone density it’s probably a good chance you’re going to
break something (male, age 60, persister).
Without any treatment, I would probably have a higher risk [of a future fracture]
(female, age 51, persister).
Oh very high, yeah. Super high, yup (male, age 76, persister).
Continue prescription treatment even if future
fracture occurs
If it wasn’t getting better or at least not getting worse, I guess I could be happy
with that (male, age 60, persister).
No to minimal risk (i.e., no side effects) I’ve been on [prescription treatment] for, I don’t know how long, two years. And
I don’t seem to be suffering any ill effects from anything that I’m taking that
I’m aware of any way (female, age 68, persister).
I just took it and like I say I didn’t experience any side effects (female,
age 58, persister).
Risks outweighed benefits for patients who
stopped
Prescription treatment is optional I wasn’t up against the wall because my condition was just sort of borderline, you
know. If I had had OP per se, I’d probably would’ve kept going [with prescription
treatment], tried a bit more (female, age 70, stopper).
[Prescription treatment] might have been recommended but there’s a subtle difference
between recommendation and requirement. And so, you know, I don’t feel that I
was required to take this drug. It was suggested to me so…I know of course it’s
not an infectious disease. But if you have tuberculosis, you know treatment is
required. It’s not recommended. You know? There’s a difference there (female,
age 57, stopper).
Perceived low risk of future fracture without
prescription treatment
I think it’s low because I don’t do anything risky. I don’t do anything that I think
would cause the any broken bones or fractures. So I think it would be low
(male, age 67, stopper).
Probably between medium and low. Because I’m not gonna stop doing things. So
but I’m more aware of safety. Yep (female, age 70, stopper).
Perceived risk: reported side effects Well that one [medication] made me sick and I talked to the person who prescribed
[it to] me and they said BWell if you’re getting sick with it, just discontinue it^
and I decided that it might help me in the long run, but I think I’ll just uh do what
does not make me feel ill… Especially if you can’t really see the results (laughing)
(male, age 67, stopper).
I was quite game to try something to make my bones stronger, sure. But, I was aware
that I had got an ulcer once with [prescription OP] medication and I had tried,
I think they had another medication that had Fosamax in it that had something to
protect the stomach and it didn’t work either and it’s just as I kept trying something
I just decided this is not worth it (female, age 70, stopper).
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According to the Information, Motivation and Behavioral
Skills model [32], people are more likely to initiate and
maintain health-promoting behaviors, including medication
adherence [33, 34], which produce positive outcomes when
Table 2 (continued)
Codes and sub-codes Selected supporting quotes
Theme 3—Re-evaluation of severity and impact
OP vs risks and benefits of treatment over time
Prescription treatment restarted 1-year post-
fragility fracture
Diagnosed with OP, not osteopenia and
prescription treatment is required
Towards the end of May [2015], I went in for my annual physical and my doctor did
the mammogram, bone density, etc. again. And I have gone from osteopenia to
OP. So I started the medication (female, age 68, changed to persister).
I know I have OP (female, age 63, changing to persister).
The other deciding factor for me with a number of things is always been I have no
family history, my doctors have always sort of aired on the side of caution, and
where [my family physician] sort of said Bit’s up to you [to take prescription
treatment]^ last year, to BI want to you to be taking it^… She would still never force
me, but before it was Byou might think about taking this.^ This year it was BI really
want you to take this^ (female, age 68, changed to persister).
Prescription treatment stopped 1-year post-fragility
fracture
Diagnosed with osteopenia, bone health has not
deteriorated, prescription treatment is options,
experienced side effects
My bone density had not changed in the last two years so I have not receded or I
haven’t gone downhill, I guess. So I will just assess again when I have my next one.
If I end up being specifically diagnosed with OP, I guess I will have to reassess or see
what else is out there and try but at this point in time I’m just gonna hang tough just
with the calcium and the Vitamin D (female, age 55, changed to stopper).
Not at this point in time, no [prescription treatment is not required] (female, age 55,
changed to stopper).
I did continue to take the Alendronate up until about 2 months ago. I was okay but I
was noticing I had some discomfort…I had a pain in my left femur… I stopped
[taking Alendronate] and I have no discomfort in my leg or my hip at all. I feel
fine (female, age 55, changed to stopper).
Potential to stop prescription treatment in the future
Relapse in taking prescription treatment Now I have to admit, that we went to Australia and New Zealand and I forgot
about 3 [weeks] of them (female, age 67, persister).
Well, I mean, (laughing) I had a brief hiatus for about 3 months where I was away,
I didn’t do it all but then came back to it. So no, in the back of mind I think it’s
the right thing to do (laughing)… It’s not an everyday thing and it just happens
[I that forget] and since it’s not life threatening it’s like BOh well, I’ll get it when
I come home^ (female, age 51, persister).
Other reasons to stop (e.g., experience side effects,
no change in bone density)
The only thing would be the side effects or the interactions with other medication
that might be more necessary. As you get older, you need sometimes more drugs
or the stomach can’t take it anymore or something (male, age 60, persister).
I haven’t been taking [prescription treatment] that long so you have to give it some
time to undo damage or do damage. So right now, I probably still say well, BIt’s
still working.^ If I three or four years from now if I had all the X-rays and things
didn’t look any different, then you might question it (female, age 51, persister).
Potential to re-start prescription treatment
Related to thefollowing conditions: decline in bone
density, informed that prescription treatment is best
option, or OP could have a negative impact
If I have a change in my bone density and [my family physician] says BYes, you will
or you need to be on it,^ okay, I will be, but I’m not now (female, age 55, changed
to stopper).
I’d be willing to do it. I think if it was a dire situation and it was explained to me that it
was a dire situation, I’d probably still be on that medication you gave me
(male, age 67, stopper).
To be honest, on the odd occasion I think, BI should go back and start you know
integrating [prescription treatment] into my life again.^ I should figure out how to
take care of this because again, I want to live a healthy life for as long as I live. But
in the whoosh of things, it gets swept aside (female, age 57, stopper).
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they are well-informed, motivated to act, and possess the skills
and confidence to take action. Perhaps the most important
insight gained from our study is that even in a healthy, knowl-
edgeable, and well-informed high-risk population with recent
fragility fracture, the decision to start and then persist with
long-term treatment is not a binary Byes-or-no^ process situ-
ated at one point in time (i.e., the diagnostic moment). Rather,
patients appear to re-evaluate and re-frame their willingness to
adhere to OP medications over time based on the perceived
severity and impact of OP on the one hand vs the risks and
benefits of bisphosphonate treatment on the other.
The results also suggest that these risk-benefit re-as-
sessments are driven by multiple factors related to time.
First, time from the clinical fracture likely plays some
role: as the memory of the clinical fracture event fades,
the perceived severity diminishes. Second, the potential
negative impact of OP also diminishes over time while the
risks of bisphosphonate treatment become more promi-
nent over time, particularly since the absence of another
fracture is the only tangible benefit of ongoing treatment.
This has implications for facilitating patient-centered de-
cision-making [35, 36] beyond the diagnostic moment
where ongoing clinical dialog is going to be needed to
support persistence and to continuously re-engage pa-
tients who stop treatment. This finding is particularly rel-
evant as demonstrated by a recent front-page article in
The New York Times reporting that people tend to avoid
effective osteoporosis treatment based on the fear of ex-
tremely rare side effects and calling for a more balanced
perspective in weighing the favorable benefit-to-risk pro-
file of treatment [37].
Similar to our findings, others have found that patients
misunderstood their diagnosis in the context of having suf-
fered a fragility fracture [38, 39]. As such, as suggested by an
expert consensus [23], our findings indicate we should use
the term Bclinical OP^ and refrain from using or overly em-
phasizing BMD test result labels such as Bosteopenia^ when
designing patient-directed interventions or educational mate-
rials. Others have also found that patients did not consider OP
serious [17, 40–42]. For example, Sale et al. found that pa-
tients did not consider compromised bone health as serious,
although this perception was not related to use of OP medi-
cations [17] possibly explaining why we found this opinion
common to both persisters and stoppers. In addition, other
studies have commented on the challenges of appropriately
treating a clinically silent disease [39, 43, 44]. Challenges
related to persistence in taking long-term OP medications
are not necessarily unique and seem similar to the problems
with adherence and persistence demonstrated for other chron-
ic conditions that are also Basymptomatic^ such as hyperten-
sion or dyslipidemia [45, 46].
Patients may also under-estimate their fracture risk or per-
ceive themselves as immune to the effects of OP [43]. Indeed,
other studies have shown that patients believed that the frac-
ture was unavoidable and caused by non-preventable circum-
stances [40, 41] and, therefore, within the realm of normal
everyday occurrence. Conversely, patients may also believe
the fracture was related to their own unsafe behaviors and,
therefore, within their control to modify to prevent the next
fracture [41, 43]. However, both of these rationalizations ne-
glect the fact that healthy bones would not have fractured
under the same low trauma circumstances.
In addition, patients appear to re-evaluate risks vs benefits
of treatments for OP over time, and it is already known that
patients are very concerned about possible or perceived (vs
actual) side effects of bisphosphonates, and this strongly in-
fluences their decisions regarding treatment persistence














Persist or restart prescription 
treatment
Stop prescription treatment
2. Reassessment over time
High
Low
Fig. 1 Conceptualization of the decision-making process to persist with, stop, or re-start prescription treatment for clinical OP over time
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patients’ risk-benefit analysis relates to their belief about
whether treatment with bisphosphonates is required (rather
than Boptional^) to decrease their risk of another fracture.
This finding has implications for the design and content of
interventions intended to promote persistence among patients
who have started treatment regardless of their concerns related
to potential or actual side effects. Clearly, OP medication use
varies over time with patients starting, stopping, and re-
initiating treatment [15, 20, 47, 50, 51]. This process of re-
evaluation might be considered promising by some (because
patients who stopped bisphosphonates may re-start) although
others believe that it is very concerning [15, 47]. For example,
Klop et al. found that persistence after re-starting OP medica-
tions remained low and was substantially lower than initial
rates of persistence [15].
Despite its strengths (grounded theory approach, theoretical
sampling, uniform patient population), our work has limita-
tions. First, even by the standards of qualitative inquiry, some
might consider our sample small; however, we sampled until
data saturation was reached, employedmultiple checks for rigor
and validity, and selected participants from both ends of the
persistence spectrum. Second, it was somewhat difficult to
use the technique of theoretical sampling within the constraints
of an ongoing trial. For example, we were unable to sample for
patients who changed treatment status more than 1 year after
their fracture and we had no access to patients who dropped out
of the study altogether. Third, we did not set out to specifically
examine sex and gender differences in health behaviors. While
this is an important area of inquiry, by our grounded theory
design, no sex or gender differences in pill-taking behavior
were evident in our study, so we did not pursue increased sam-
pling of constructs related to sex and gender. Last, all subjects
were relatively healthy, of good socioeconomic status, had
good knowledge related to osteoporosis, had no contraindica-
tions to bisphosphonate treatment, and all had an upper extrem-
ity fragility fracture, and our findings were based on the expe-
riences of trial patients with universal healthcare coverage from
one Canadian province. Thus, some might not consider our
results transferrable to other populations, including patients
with other types of fractures including hip or spine or settings.
The processes and reasoning related to persisting with or
stopping bisphosphonate treatment for OP after a fragility
fracture are complex and dynamic over the long term. Our
findings suggest two potential areas to leverage for providers
and those designing interventions. First, healthcare providers
should reinforce the severity and risks and potential harms
related to untreated clinical OP and refrain from using BMD
test-based labels such as osteopenia, which appears to dimin-
ish perceived disease severity among patients. Second,
healthcare providers need to review regularly the very favor-
able benefit-to-risk profile of treatment for this high-risk
group of patients. Perhaps what has become most clear
through this research is that starting treatment for OP is the
beginning of a long-term negotiation with patients in an effort
to prevent the next fracture and its potential consequences.
Acknowledgments SRM holds the Endowed Chair in Patient Health
Management funded by the Faculties of Medicine and Dentistry and
Pharmacy and Pharmaceutical Sciences of the University of Alberta.
JAJ is a Senior Scholar with Alberta Innovates-Health Solutions
(AIHS) and a Centennial Professor at the University of Alberta. FAM
holds the Endowed Chair in Cardiovascular Outcomes Research at the
University of Alberta and is a Senior Health Scholar of AIHS. LAB is
supported by the Canadian Institutes of Health Research (CIHR) as a
New Investigator and by AIHS as a Population Health Investigator.
BHR is a Tier I Canada Research Chair in Evidence-Based Emergency
Medicine supported by CIHR and Government of Canada (Ottawa, ON).
This work was supported by peer-reviewed grants from the AIHS
Partnership for Research and Innovation in the Health System and
Alberta Health.
Compliance with ethical standards
Conflict of interest None
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and
indicate if changes were made.
Table 3 Selected questions from interview guide
Questions posed to all patients
1. Tell me about your understanding of your diagnosis.
2. (If BI don’t have OP^): what is the difference between your current
condition and OP?
3. Tell me why you decided to start bisphosphonate treatment.
4. Are you concerned about having another fall and breaking another
bone? Why?
5. What do you consider your risk of having another fracture without
bisphosphonate treatment?
6. How do you think OP or the weakening or thinning of bones, will
affect you over the course of your life?
7. Do you think bisphosphonate treatment is required for you to treat OP?
Why or why not?
8. How serious is OP as a health condition?
Questions posed to patients who persisted with prescription treatment
1. Tell me about why you decided to keep taking a bisphosphonate as part
of your treatment.
2.What, if anything, would make you decide to stop the bisphosphonate?
Questions posed to patients who stopped prescription treatment
1. Tell me about why you decided to stop taking a bisphosphonate as part
of your treatment.
2. What, if anything, would make you decide to take a bisphosphonate
again?
Appendix
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